References
- Reyes H. Sex hormones and bile acids in intrahepatic cholestasis of pregnancy. Hepatology. 2008;47:376–379.
- Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J Gastroenterol. 2009;15:2049–2066.
- Geenes V, Chappell LC, Seed PT, et al. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology. 2014;59:1482–1491.
- Dixon PH, Williamson C. The pathophysiology of intrahepatic cholestasis of pregnancy. Clin Res Hepatol Gastroenterol. 2016;40:141–153.
- Koshimizu TA, Nakamura K, Egashira N, et al. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92:1813–1864.
- Laycock JF. Perspectives on vasopressin. London, UK: World Scientific; 2009.
- Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19:43–49.
- Goulis DG, Walker IA, de Swiet M, et al. Preeclampsia with abnormal liver function tests is associated with cholestasis in a subgroup of cases. Hypertens Pregnancy. 2004;23:19–27.
- Wikström Shemer E, Marschall HU, Ludvigsson JF, et al. Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG. 2013;120:717–723.
- Martineau M, Raker C, Powrie R, et al. Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. Eur J Obstet Gynecol Reprod Biol. 2014;176:80–85.
- Yesil A, Kanawati A, Helvacioglu C, et al. Identification of patients at risk for preeclampsia with the use of uterine artery Doppler velocimetry and copeptin. J Matern Fetal Neonatal Med. 2016. DOI:10.1080/14767058.2016.12628411-6
- Ebert T, Platz M, Kralisch S, et al. Serum levels of copeptin are decreased in gestational diabetes mellitus. Exp Clin Endocrinol Diabetes. 2016;124:257–260.
- Zulfikaroglu E, Islimye M, Tonguc EA, et al. Circulating levels of copeptin, a novel biomarker in pre-eclampsia. J Obstet Gynaecol Res. 2011;37:1198–1202.
- Tuten A, Oncul M, Kucur M, et al. Maternal serum copeptin concentrations in early- and late-onset pre-eclampsia. Taiwan J Obstet Gynecol. 2015;54:350–354.
- Yeung EH, Liu A, Mills JL, et al. Increased levels of copeptin before clinical diagnosis of preeclampsia. Hypertension. 2014;64:1362–1367.
- Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3:1035–1078.
- Floreani A, Gervasi MT. New insights on intrahepatic cholestasis of pregnancy. Clin Liver Dis. 2016;20:177–189.
- Gewirtz DA, Randolph JK, Goldman ID. Induction of taurocholate release from isolated rat hepatocytes in suspension by alpha-adrenergic agents and vasopressin: implications for control of bile salt secretion. Hepatology. 1984;4:205–212.
- Nakazawa T, Hoshino M, Hayakawa T, et al. Vasopressin reduces taurochenodeoxycholate-induced hepatotoxicity by lowering the hepatocyte taurochenodeoxycholate content. J Hepatol. 1996;25:739–747.
- Hiroyama M, Aoyagi T, Fujiwara Y, et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol. 2007;21:247–258.
- Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol. 1993;14:76–122.
- Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res. 1998;30:360–367.
- Montero S, Mendoza H, Valles V, et al. Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide. J Appl Physiol. 2006;100:1902–1909.
- Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94:2558–2564.
- Lu Y, Zhang Z, Xiong X, et al. Glucocorticoids promote hepatic cholestasis in mice by inhibiting the transcriptional activity of the farnesoid X receptor. Gastroenterology. 2012;143:1630–1640. e1638.